AVEO announces dosing of first patient in pivotal phase 3 TIVO-3 study of tivozanib
AVEO Oncology announced the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma. May 26, 2016